A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer Patients Without Life-Prolonging Therapies of Demonstrated Clinical Benefit (PAYLOAD)
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Irinotecan (Primary) ; RRx 001 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- Acronyms PAYLOAD
- Sponsors EpicentRx
- 06 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 06 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 06 Sep 2017 Status changed from not yet recruiting to recruiting.